Peptide education
HGH Fragment 176-191
HGH Frag 176-191 · HGH Fragment
HGH Fragment 176-191 is the unmodified C-terminal tail of human growth hormone, sold widely as a fat-loss peptide. The catch: almost none of the human evidence studies this molecule. The trials people cite belong to AOD-9604, a modified analogue with an extra tyrosine, and even that borrowed evidence is weak, because the analogue's larger obesity trial was negative. What remains is a market name resting on preclinical history and a discontinued drug program.
No direct human study of native HGH Fragment 176-191 appears in the reviewed record. Its fat-loss reputation is borrowed from AOD-9604, a modified analogue whose own larger obesity trial missed, so the market name runs on evidence that was never about this molecule.
Overview
Quick answer
Native HGH Fragment 176-191 and AOD-9604 are related, but they are not the same molecule. AOD-9604 adds an N-terminal tyrosine and carries most of the human obesity, safety, and regulatory discussion. Start by checking whether a source is talking about the native fragment, AOD-9604, LAT8881, a compounded salt form, or a gray-market vial using the shorter "HGH frag" name.
What is HGH Fragment 176-191?
The short C-terminal segment of human growth hormone, the region tied to lipolytic signaling in older animal and cell work. When development moved into human obesity trials, the molecule tested was a modified analogue, AOD-9604, not this native fragment.
Which name is the source actually using?
Three names carry three different evidence loads: native HGH Fragment 176-191, which has no direct human efficacy publication in the reviewed material; AOD-9604 or LAT8881, the modified analogue with human studies and a negative larger trial; and market HGH frag listings, which are seller claims until the product can be tied to studied material.
What do people use it for or talk about?
Fat loss, stubborn fat, waist size, body composition, metabolism, and weight-management stacks. Clinic and gray-market sources add repair, cartilage, recovery, anti-aging, and skin claims, none of which has human data behind it.
What dose patterns show up in the sources?
The human studies, all for the AOD-9604 analogue, used defined oral and IV exposures. FDA-reviewed materials describe advertised injectable, oral, and transdermal products; those show what is sold, not which route works in people.
Why are the products not interchangeable?
Because identity, evidence, and product are three separate checks. The native fragment lacks direct human data, the analogue's efficacy result was weak, and any vial, capsule, or cream still has to prove what it contains.
Reported practice
Commonly reported protocol
Community fat-loss and recomposition protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
FDA and registry materials describe AOD-9604/LAT8881 as a modified analogue, while the native HGH Fragment 176-191 identity is a separate chemistry question.
Those results come from a modified analogue program, so they do not transfer directly to the unmodified native fragment sold under many "HGH frag" listings.
The related AOD-9604 program reported an early 12-week signal, but the larger 24-week OPTIONS obesity study missed its primary endpoint and the obesity program was stopped.
Subcutaneous, oral-capsule, and transdermal market examples appear in FDA materials and online advertising, but FDA did not identify human exposure data for subcutaneous or transdermal compounded products.
FDA noted salt-form, COA, identity, impurity, aggregation, microbial, and endotoxin questions for AOD-9604-related compounded products.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| HGH Fragment 176-191 is clinically established for fat loss. | No direct human clinical efficacy publication for the native fragment is available. The human obesity evidence usually cited for this name comes from AOD-9604/LAT8881, and even that evidence is weak: a larger randomized OPTIONS study missed a statistically significant weight-loss advantage over placebo. | Older animal studies of C-terminal growth-hormone fragments and later AOD-9604 rodent work support why fat-metabolism claims became plausible. Rodent signals cannot show that native HGH Fragment 176-191 produces meaningful fat loss in people. | Clinic pages, vendor listings, Reddit threads, forum posts, and med-spa marketing commonly describe fat loss, body recomposition, waist change, and "stubborn fat" use. Those reports show what people are trying, not whether the effect is real. | The fat-loss claim runs ahead of the evidence. The direct native fragment human evidence is missing and the related analogue failed to show convincing obesity efficacy. |
| HGH Fragment 176-191 is the same as AOD-9604. | The human studies and later LAT8881 protocols concern the modified analogue. They do not by themselves become direct evidence for the native HGH Fragment 176-191 molecule. | The molecules are related through the C-terminal growth-hormone fragment idea, but a modified analogue can differ in sequence, salt form, stability, exposure, and biological behavior. | Online sellers and forum users often use "HGH fragment," "hGH 176-191," and "AOD-9604" close together. That shorthand is common enough to explain, but too loose for evidence claims. | This shorthand is misleading because the molecular relationship does not make the human studies, routes, safety evidence, or product-quality evidence interchangeable. |
| Subcutaneous HGH Fragment 176-191 or AOD-9604 is clinically studied for weight loss. | FDA's 2024 review did not identify human exposure data for subcutaneous or transdermal compounded AOD-9604 products. The historical human obesity studies used oral dosing, and early safety work included IV dosing. | Route changes exposure, degradation, immune presentation, and product risks. A peptide with oral and IV history may behave differently when sold as a compounded injectable vial. | Subcutaneous use is common in clinic, med-spa, Reddit, forum, and gray-market discussion. FDA-reviewed materials included injectable market nominations, but those examples show market demand rather than human route evidence. | Subcutaneous use is a current market route, but the available human weight-loss data are oral and IV rather than subcutaneous. |
| It burns fat without affecting IGF-1 or glucose. | Historical AOD-9604 oral and IV studies reported little signal for IGF-1 elevation or worsening glucose tolerance in the studied settings. That is a route-limited analogue observation and does not automatically carry over to native HGH Fragment 176-191, compounded injections, topical products, or long-term use. | The development idea was to separate fat-metabolism effects from the broader endocrine effects of full-length growth hormone. Older native fragment work also included glucose and insulin signals in animals, so the biology is not as simple as "fat only." | Vendor and clinic pages often turn the IGF-1 point into broad "no GH side effects" marketing. FDA's review leaves more safety questions open than that marketing implies. | Partly grounded in the specific analogue studies, but overbroad when applied to every product, route, or long-term use scenario. |
| It repairs cartilage, joints, or soft tissue. | Human clinical support for repair or recovery claims is missing. | A rabbit osteoarthritis model exists for AOD-9604, and later LAT8881 pain research has a preclinical mechanism thread. That is animal and development-context evidence, not human joint repair evidence for the native fragment. | Repair, cartilage, muscle recovery, and anti-aging claims appear in clinic and gray-market discussion. They are not backed by the available human studies. | Repair and recovery claims remain animal or market claims; the available human material does not show benefit. |
| What can a COA tell you about vial quality? | This is a product-quality issue rather than a clinical-efficacy issue. FDA found confusion between free base and acetate, mismatched COA details, and missing characterization information. | A purity percentage misses the questions quality review needs: salt form, sequence confirmation, peptide-related impurities, aggregation, microbial testing, endotoxin, sterility, fill accuracy, storage, and degradation. | Vendor pages commonly advertise purity or provide a COA. That can be one narrow data point for one sample, but it does not make the product match a clinical trial material or a regulated injectable product. | A COA may support a narrow batch claim, but injectable, oral, or topical products still need route-specific quality checks and evidence in people. |
Bottom line
Main takeaway
HGH Fragment 176-191 is promoted for fat loss, but the human talking points come from a different molecule, the modified analogue AOD-9604, and even that analogue's big trial was negative.
Sort claims by molecule and by route: native-fragment claims are not AOD-9604 claims, and oral or IV study history does not cover subcutaneous, topical, capsule, clinic, or gray-market products.
The core sources are FDA's 2024 AOD-9604 review, the Stier human safety summary, the Metabolic sponsor-era obesity documents, the LAT8881 registry protocols, the exact-fragment animal and cell literature, and FDA's product-quality critique.
Identity
What it is
HGH Fragment 176-191 is the native C-terminal segment of human growth hormone: the tail region linked to fat metabolism in animal work, without the receptor-engaging machinery of the full hormone.
That missing machinery is both the pitch and the problem. The fragment was supposed to deliver fat effects without growth hormone's endocrine effects; the same incompleteness is a reason to doubt its potency, and no human trial of the native fragment has answered the question.
The human data that exist belong to AOD-9604, a modified analogue with an added tyrosine, and those data end in a discontinued obesity program. When a vendor cites studies while selling HGH frag, the citation and the product usually describe different molecules.
The blur deepens when animal data, COAs, and anecdotes get stacked as if they all proved the same product claim.
How people talk about it online
The conversation is fat loss: body composition, waist change, stubborn fat, cutting phases, and stacks with other weight-management or GH-axis peptides. Reddit and forum reports are personal-use logs with inconsistent product identity and dose reporting.
Clinic, med-spa, and vendor pages extend the name to cartilage, joints, recovery, skin, anti-aging, glucose, and cholesterol. FDA materials describe similar advertising themes around AOD-9604-related products, and advertising themes are not benefit data.
Route claims are where the confusion turns concrete. Listings sell subcutaneous vials, capsules, creams, and oral-dissolving products, while the historical human studies for the analogue were oral, with early IV single-dose safety work.
Use context
Routes, doses, and cycle patterns
Route and dose details have to stay tied to the source. Human AOD-9604 studies used oral daily schedules and IV single-dose safety designs. FDA-reviewed market materials describe subcutaneous, oral-capsule, and transdermal compounded or advertised products. Forums and vendor pages discuss fat-loss cycles, but not with enough consistent product identity, route, amount, or duration to call those reports clinical evidence.
Human studies and product labels
IV single-dose safety escalation
- Purpose
- Early safety and endocrine-marker observation for AOD-9604
- Context
- Human safety study summary
- Route
- IV
- Amount
- 25 to 400 mcg/kg
- Frequency
- Single-dose designs
- Duration
- Single-dose with follow-up
These early studies looked at tolerability, IGF-1, glucose, and other safety markers. They track safety markers rather than fat-loss efficacy, subcutaneous use, or topical use.
Short oral safety studies
- Purpose
- Oral AOD-9604 safety and pharmacodynamic exploration
- Context
- Human safety study summary
- Route
- Oral
- Amount
- 9, 27, or 54 mg
- Frequency
- Single dose or once daily
- Duration
- Single dose or 7 days
These small studies help with short-term tolerability and markers such as IGF-1 and glucose handling. They were not long obesity outcome trials.
12-week oral obesity study
- Purpose
- Obesity and body-weight outcomes for AOD-9604
- Context
- Sponsor-era randomized obesity study
- Route
- Oral
- Amount
- 1, 5, 10, 20, or 30 mg
- Frequency
- Once daily
- Duration
- 12 weeks after placebo run-in
Sponsor materials described modest or non-linear signals, but FDA later characterized the public efficacy detail as sparse and hard to interpret.
24-week OPTIONS obesity study
- Purpose
- Obesity and weight-loss efficacy for AOD-9604
- Context
- Larger randomized obesity study
- Route
- Oral
- Amount
- 0.25, 0.5, or 1 mg
- Frequency
- Once daily
- Duration
- 24 weeks with diet and exercise program
This is the major human efficacy result. The study missed a statistically significant weight-loss difference at the 12-week primary endpoint, and obesity development was later terminated.
Real-world discussion
Community fat-loss and recomposition protocols
- Purpose
- Fat loss, usually fasted-cardio or cutting framing
- Context
- Forums, vendor listings, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- The common community pattern is 250 to 500 mcg per injection, one to two times daily, usually fasted or before cardio.
- Frequency
- Once or twice daily in most community descriptions
- Duration
- Most runs are 8 to 12 week cycles
The fragment has no solid human outcome trials for fat loss, and the fasted timing convention comes from mechanistic reasoning about insulin, not from clinical evidence. That is the reported picture, not advice.
What varies
- Identity: native HGH Fragment 176-191, AOD-9604, LAT8881, free base, acetate, and vendor shorthand can point to different products.
- Goal: fat-loss and body-composition claims have more source material than repair or anti-aging claims, but the human efficacy result is still weak.
- Route: the human study history is oral and IV; subcutaneous, topical, capsule, and oral-dissolving market products need their own evidence.
- Amount: study amounts range from mcg/kg IV single doses to oral mg/day schedules; market examples use concentration or product-unit language that cannot be compared directly.
- Product quality: identity, salt form, sterility, endotoxin, impurities, aggregates, storage, and reconstitution matter more than a purity percentage alone.
Human data
Human evidence
No peer-reviewed human efficacy or safety publication for the exact native fragment was found. The relevant human data belong to AOD-9604: oral and IV safety studies that stayed mostly quiet for IGF-1 and glucose markers, a 12-week obesity study with a modest sponsor-reported signal, and the larger OPTIONS trial that missed its primary endpoint, after which development was terminated. FDA's 2024 review then flagged quality gaps in compounded subcutaneous and transdermal products, the routes the current market favors most.
Evidence maturity
The native fragment has no direct human trials at all, and even the borrowed AOD-9604 evidence ends in a failed obesity program.
Animal and cell studies of C-terminal growth-hormone fragments built the fat-metabolism hypothesis between 1978 and 1994.
The cited human data belong to AOD-9604, a modified analogue, whose oral and IV safety studies were mostly tolerable.
AOD-9604's larger 24-week OPTIONS obesity trial missed its primary endpoint and development was terminated.
None was found; no direct human efficacy or safety publication exists for the exact native fragment.
Subcutaneous, oral, and transdermal 'HGH frag' products sell on borrowed analogue data while FDA flags identity and quality gaps.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Native HGH Fragment 176-191 human evidence | No human study population was identified for native HGH Fragment 176-191 itself | Human data come from AOD-9604/LAT8881, not native HGH Fragment 176-191 itself | Native fragment / unclear market products | No peer-reviewed human efficacy or safety publication is available for the exact native fragment. | There is too little human evidence here for confident claims about the native fragment. | Weak |
| METAOD001 and METAOD002 IV AOD-9604 studies | Healthy or obese male volunteers in small early studies | Human safety studies | Investigational analogue | IV single-dose studies reported tolerability observations and no clear IGF-1 or glucose signal in summaries. They were safety summaries, not fat-loss efficacy trials. | Small, short, analogue-specific, and not applicable to modern subcutaneous or transdermal products. | Weak |
| METAOD003 and METAOD004 oral AOD-9604 studies | Clinically obese male volunteers in small oral studies | Human safety and short-course pharmacodynamic studies | Investigational analogue | Oral single-dose and 7-day schedules reported mostly mild or moderate adverse events and no significant IGF-1 changes in summaries. | These were short safety studies, not long-term body-composition trials. | Weak |
| METAOD005 12-week obesity study | About 300 adults with obesity | Randomized placebo-controlled obesity study | Investigational analogue | Sponsor-era materials described modest weight and waist signals, but FDA later said the public data were minimal and hard to interpret. | Public efficacy reporting is sparse and sponsor-derived, and the result did not carry the program after the later study. | Weak |
| METAOD006 OPTIONS obesity study | About 502 randomized adults with obesity | Randomized placebo-controlled obesity study | Investigational analogue | The study missed a statistically significant weight-loss difference at the primary 12-week endpoint, and obesity development was terminated. | This is analogue evidence, not native-fragment evidence, but it is still the most important human obesity result in the cited study. | Weak |
| Rabbit osteoarthritis model | Rabbits in an osteoarthritis model | Animal study | AOD-9604 analogue | The animal study gives preclinical joint or cartilage context, not human repair claims. | Animal joint findings do not translate into human recovery, muscle, or cartilage benefit. | Preclinical |
Cautions
Safety and unknowns
- FDA found no human pharmacokinetic data and no human exposure data for subcutaneous or transdermal compounded AOD-9604 products, which matters because those routes dominate current market discussion.
- Historical AOD-9604 human studies looked relatively quiet for IGF-1 and glucose markers in oral and IV settings, but those findings leave long-term, injectable, topical, and native-fragment safety unanswered.
- FDA described important questions around immunogenicity, peptide-related impurities, aggregation, microbial testing, endotoxin testing, and long-term use in a chronic condition like obesity.
- FDA noted cancers in one historical oral study and stated that available information was insufficient to determine whether those events were unrelated to AOD-9604.
- Some company-linked nonclinical papers read more reassuringly than FDA's later review, which still raised mutagenicity, rat bone-health, and possible monkey liver-toxicity questions.
- Repair, cartilage, recovery, skin, and anti-aging claims add risk because they move the product into areas with little or no direct human support.
Product quality
A vial label is only a starting point
FDA found confusion between AOD-9604 free base and acetate in nomination materials, including COA details that did not cleanly match the nominated substance.
Public purity claims leave identity, salt form, impurity profile, aggregation behavior, sterility, endotoxin control, fill amount, stability, shipping conditions, and correct reconstitution unresolved.
A vial sold as "HGH frag" may be native HGH Fragment 176-191, AOD-9604, a salt form, a mislabeled product, or a mixture whose relation to the human study material is unclear.
Identity
The native fragment, AOD-9604, LAT8881, free base, and acetate are not interchangeable labels for evidence claims.
Route and sterility
Subcutaneous products raise sterility, endotoxin, aggregation, and immune-presentation questions left unanswered by oral and IV study summaries when the product is a gray-market vial.
COA limits
A purity number can miss salt-form mismatch, sequence error, impurity profile, microbial status, degradation, storage, fill volume, and batch chain of custody.
Concentration and dose math
Market examples use vial concentration, capsule amount, or cream strength, while studies used mg/day oral dosing or mcg/kg IV dosing. Those units cannot be loosely converted into equivalent use.
Mechanism
How it is proposed to work
The basic idea is that the C-terminal region of growth hormone may influence fat metabolism without acting like full-length growth hormone. Older native fragment studies and later AOD-9604 animal studies make that idea biologically plausible, but the human obesity program did not turn it into a convincing treatment result.
Early work with C-terminal growth-hormone fragments in animals reported glucose, insulin, anti-lipogenic, and body-weight effects. That history is more complex than the common claim that the fragment is purely fat-selective.
AOD-9604 rodent studies reported reduced body-weight gain, increased lipolysis or fat oxidation, limited classical GH-receptor activity, and a beta-3 adrenergic receptor connection. Those findings support a preclinical metabolic rationale.
Human mechanism remains poorly characterized. FDA later noted the lack of adequate human PK and PD data, especially for compounded subcutaneous and transdermal products.
Later LAT8881 neuropathic-pain research describes a separate preclinical mechanism thread involving LANCL1. That work is not human fat-loss, repair, or recovery evidence for native HGH Fragment 176-191.
HGH Fragment 176-191 is the unmodified C-terminal tail of growth hormone, the region associated with lipolytic signaling. It lacks the receptor-engaging determinants of full-length GH, which is both its claimed safety feature and the reason its potency is doubtful.
FAQ
Common questions
Is HGH Fragment 176-191 the same as AOD-9604?
No. AOD-9604 is a modified version of the same fragment that actually went through human obesity trials. The unmodified 176-191 fragment discussed online has no human clinical literature of its own.
What do reported schedules look like?
Community protocols commonly describe 250 to 500 mcg per injection, one to two times daily, usually fasted or before cardio, in 8 to 12 week cycles.
Does HGH Fragment 176-191 have human evidence?
No meaningful human outcome evidence. The fat-loss rationale is extrapolated from growth-hormone biology and from the failed trials of its modified derivative.
Details
Technical details
Sources
References
- 1.
FDA PCAC 2024. FDA PCAC AOD-9604 briefing document, 2024.
Core regulatory, safety, quality, and effectiveness assessment
- 2.
FDA PCAC transcript. FDA PCAC transcript and presentation.
Gray-market advertising, GRAS clarification, compounding remarks
- 3.
Stier 2013. Stier et al., 2013, human safety summary.
Historical human safety, IGF-1, glucose, and route details
- 4.
Metabolic 2005. Metabolic 2005 annual report and conference release.
Sponsor-era efficacy framing for 12-week obesity study
- 5.
Metabolic OPTIONS. Metabolic 2007 OPTIONS documents.
Negative large obesity study and termination context
- 6.
LAT8881 registries. ClinicalTrials.gov LAT8881 protocols, 2019 and 2023.
Later formal protocol summaries, study counts, and repurposing history
- 7.
Ng 2000. Ng et al., 2000, Horm Res.
Rodent metabolic rationale for AOD-9604
- 8.
Heffernan 2001 obesity. Heffernan et al., 2001, Int J Obes.
Rodent fat-oxidation and receptor-independence story
- 9.
Heffernan 2001 receptor. Heffernan et al., 2001, Endocrinology.
Beta-3-adrenergic receptor dependence
- 10.
Exact-fragment early papers. Exact-fragment era papers, 1978 to 1994.
Native-fragment mechanistic and metabolic history
- 11.
OA rabbit model. Rabbit osteoarthritis model, 2015.
Limits of repair and recovery claims
- 12.
In vitro oncology. Exact hGH 176-191 in vitro oncology paper, 2022.
Modern exact-fragment literature, but nonclinical and off-topic for fat loss
- 13.
GRAS clarification. GRAS-related sources, including company press release and FDA clarification.
Regulatory clarification on GRAS language
- 14.
FTC claim enforcement. FTC HGH and weight-loss claim enforcement and guidance.
Regulatory and advertising-risk context for overextended HGH and weight-loss claims
- 15.
Gray-market examples. Gray-market anecdote and clinic examples.
Shows claims circulating in clinics, forums, and gray-market listings